Cargando…
Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or s...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102104/ https://www.ncbi.nlm.nih.gov/pubmed/21633514 http://dx.doi.org/10.1371/journal.pone.0020200 |
_version_ | 1782204349603119104 |
---|---|
author | Beck, Eduard J. Mandalia, Sundhiya Lo, Gary Sharott, Peter Youle, Mike Anderson, Jane Baily, Guy Brettle, Ray Fisher, Martin Gompels, Mark Kinghorn, George Johnson, Margaret McCarron, Brendan Pozniak, Anton Tang, Alan Walsh, John White, David Williams, Ian Gazzard, Brian |
author_facet | Beck, Eduard J. Mandalia, Sundhiya Lo, Gary Sharott, Peter Youle, Mike Anderson, Jane Baily, Guy Brettle, Ray Fisher, Martin Gompels, Mark Kinghorn, George Johnson, Margaret McCarron, Brendan Pozniak, Anton Tang, Alan Walsh, John White, David Williams, Ian Gazzard, Brian |
author_sort | Beck, Eduard J. |
collection | PubMed |
description | AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line PI(boosted) regimens. METHODS: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PI(boosted) regimens was calculated for four CD4 strata. RESULTS: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count ≤200 cells/mm3, many of whom were Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between starting HAART with CD4 ≤200 cells/mm3 compared with CD4 count >200 cells/mm3. 2NRTI+PI(boosted) and 2NRTI+NNRTI regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective compared with 2NRTI + PI(boosted) regimens. CONCLUSION: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line HAART regimen at CD4 counts ≤350 cell/mm3, unless specific contra-indications exist. This will increase the number of PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited resources. |
format | Text |
id | pubmed-3102104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31021042011-06-01 Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006 Beck, Eduard J. Mandalia, Sundhiya Lo, Gary Sharott, Peter Youle, Mike Anderson, Jane Baily, Guy Brettle, Ray Fisher, Martin Gompels, Mark Kinghorn, George Johnson, Margaret McCarron, Brendan Pozniak, Anton Tang, Alan Walsh, John White, David Williams, Ian Gazzard, Brian PLoS One Research Article AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line PI(boosted) regimens. METHODS: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PI(boosted) regimens was calculated for four CD4 strata. RESULTS: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count ≤200 cells/mm3, many of whom were Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between starting HAART with CD4 ≤200 cells/mm3 compared with CD4 count >200 cells/mm3. 2NRTI+PI(boosted) and 2NRTI+NNRTI regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective compared with 2NRTI + PI(boosted) regimens. CONCLUSION: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line HAART regimen at CD4 counts ≤350 cell/mm3, unless specific contra-indications exist. This will increase the number of PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited resources. Public Library of Science 2011-05-25 /pmc/articles/PMC3102104/ /pubmed/21633514 http://dx.doi.org/10.1371/journal.pone.0020200 Text en Beck et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Beck, Eduard J. Mandalia, Sundhiya Lo, Gary Sharott, Peter Youle, Mike Anderson, Jane Baily, Guy Brettle, Ray Fisher, Martin Gompels, Mark Kinghorn, George Johnson, Margaret McCarron, Brendan Pozniak, Anton Tang, Alan Walsh, John White, David Williams, Ian Gazzard, Brian Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006 |
title | Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based
HAART Regimens in the UK, 1996-2006 |
title_full | Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based
HAART Regimens in the UK, 1996-2006 |
title_fullStr | Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based
HAART Regimens in the UK, 1996-2006 |
title_full_unstemmed | Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based
HAART Regimens in the UK, 1996-2006 |
title_short | Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based
HAART Regimens in the UK, 1996-2006 |
title_sort | cost-effectiveness of early treatment with first-line nnrti-based
haart regimens in the uk, 1996-2006 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102104/ https://www.ncbi.nlm.nih.gov/pubmed/21633514 http://dx.doi.org/10.1371/journal.pone.0020200 |
work_keys_str_mv | AT beckeduardj costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT mandaliasundhiya costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT logary costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT sharottpeter costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT youlemike costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT andersonjane costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT bailyguy costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT brettleray costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT fishermartin costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT gompelsmark costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT kinghorngeorge costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT johnsonmargaret costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT mccarronbrendan costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT pozniakanton costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT tangalan costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT walshjohn costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT whitedavid costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT williamsian costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT gazzardbrian costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 AT costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006 |